Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 41 out of 100. Prevention and risk

Topic: Risk, prevention and care in population studies

Plain-language summary

Statins show mixed results in CKD and ESRD, with limited benefits in reducing cardiovascular events in dialysis patients. Agents like PCSK9 inhibitors show promising results but require further research, while non-statin therapies like fibrates and omega–3 fatty acids have limited evidence for use in this population. The review underscores the need for further research into lipid-lowering agents in CKD and ESRD patients, highlighting the need for tailored lipid management strategies in vulnerable patients with unique risk factors. More studies are needed to refine treatment strategies and assess the role of exercise and accurate risk calculators in managing cardiovascular outcomes.

What this study adds

Evidence grade: Low

This review is about lipid management in chronic kidney disease and hemodialysis patients, not Alzheimer's disease, and reports no findings on dementia. It notes mixed results for statins and limited evidence for several other lipid-lowering therapies in this population.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Abidor, E., Achkar, M. A., Saidi, I. A., Lather, T., Jdaidani, J., Agarwal, A., et al. (2025). Comprehensive Review of Lipid Management in Chronic Kidney Disease and Hemodialysis Patients: Conventional Approaches, and Challenges for Cardiovascular Risk Reduction. Journal of Clinical Medicine. https://doi.org/10.3390/jcm14020643

Vancouver

Abidor E, Achkar MA, Saidi IA, Lather T, Jdaidani J, Agarwal A, et al. Comprehensive Review of Lipid Management in Chronic Kidney Disease and Hemodialysis Patients: Conventional Approaches, and Challenges for Cardiovascular Risk Reduction. Journal of Clinical Medicine. 2025. doi:10.3390/jcm14020643. PMID: 39860649.

BibTeX

@article{abidor2025-39860649,
  author  = {Abidor, Erica and Achkar, Michel Al and Saidi, Ibrahim Al and Lather, Tanvi and Jdaidani, Jennifer and Agarwal, Alaukika and El‐Sayegh, Suzanne},
  title   = {{Comprehensive Review of Lipid Management in Chronic Kidney Disease and Hemodialysis Patients: Conventional Approaches, and Challenges for Cardiovascular Risk Reduction}},
  journal = {Journal of Clinical Medicine},
  year    = {2025},
  doi     = {10.3390/jcm14020643},
  pmid    = {39860649},
  url     = {https://doi.org/10.3390/jcm14020643}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record names 7 authors; APA and Vancouver show the first six, BibTeX and the downloads carry all of them. Check the citation against the original before you use it.

Key findings

Why it matters

This review is about lipid management in chronic kidney disease and hemodialysis patients, not Alzheimer's disease, and reports no findings on dementia. It notes mixed results for statins and limited evidence for several other lipid-lowering therapies in this population.

Study details

How this study scored 41/100
How this study's score is builtJournal tier 7 of 10; Journal's citation record 2 of 4; Study design 0 of 12; Strength of evidence 1 of 5; Peer-review validation 10 of 10; How recent 4 of 5; Sample size 0 of 4; Effect reported 0 of 3; Studied in people 0 of 3; Randomized / blinded 0 of 2; Times cited 3 of 7; Citations per year 2 of 5; Impact for its field and year 4 of 6; Cited by studies here 0 of 6; Still being cited 2 of 4; Senior author's track record 1 of 4; Institution's track record 0 of 3; Multicenter collaboration 1 of 3; Indexed in PubMed 2 of 2; Free to read 2 of 2. Total 41 of 100.41 of 100 points earned59 not earned

Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it.

ComponentPointsWhy
Journal tier 7 / 10 Tier 3 — peer-reviewed journal (Journal of Clinical Medicine)
Journal's citation record 2 / 4 Journal of Clinical Medicine: journal h-index 188 (OpenAlex, 2026-10-29)
Study design 0 / 12 No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence 1 / 5 Rated “low” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 4 / 5 2025 — within 3 year(s) of the newest study here
Sample size 0 / 4 Participant count not stated — scores zero (not stated in the record — scored 0)
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 0 / 3 Not stated whether this was studied in people — scores zero (not stated in the record — scored 0)
Randomized / blinded 0 / 2 No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 3 / 7 Cited 17 times (OpenAlex, 2026-10-10)
Citations per year 2 / 5 5.7 citations a year over 3 year(s) since 2025
Impact for its field and year 4 / 6 Cited 15.2× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 0 / 6 No other study in this library cites it
Still being cited 2 / 4 Cited 17 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 1 / 4 Last-listed author Suzanne El‐Sayegh: h-index 18 (OpenAlex, whole career)
Institution's track record 0 / 3 Northwell Health: institution h-index 461 (OpenAlex)
Multicenter collaboration 1 / 3 OpenAlex lists 2 institution(s) in 1 country
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 39860649)
Free to read 2 / 2 Free to read
Total 41 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Studies in the library that share something with this one. The line above each title says what.

Related studies in Prevention and risk from nearby years

Also in Prevention and risk

269 studies in the library are filed under Prevention and risk with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Prevention and risk hub.

Similar studies

More on Prevention and risk

See all studies in Prevention and risk →